Skip to content


PVP Biologics

Health & Medicine, Life Science

CoMotion Labs - Fluke Hall




PVP Biologics (acquired by Takeda in February, 2020) is developing an oral enzyme for the treatment of celiac disease. Celiac disease is an inflammatory intestinal immune response to gluten protein contained in wheat, rye or barley, and as it affects an estimated 2.4 million Americans, celiac disease is significantly more common than inflammatory bowel disease and is associated with acute GI symptoms, malnutrition, and increased mortality. The disease is currently treated by a gluten-free diet, which is costly and challenging to maintain strict compliance. Moreover, many patients continue to report persistent symptoms despite adhering to a gluten-free diet. PvP Biologics is developing a therapeutic product designed to break down the immuno-reactive parts of gluten in the stomach and thereby avoid the painful symptoms and damage done in the small intestine from accidental gluten ingestion.

Team Members

David Baker

Co-founder, Professor of Biochemistry, University of Washington

Ingrid Swanson Pultz

Co-founder, Senior Research Fellow at Institute for Protein Design

Adam Simpson